2023
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
Ragnhildstveit A, Roscoe J, Bass L, Averill C, Abdallah C, Averill L. The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence. Therapeutic Advances In Psychopharmacology 2023, 13: 20451253231154125. PMID: 36895431, PMCID: PMC9989422, DOI: 10.1177/20451253231154125.Peer-Reviewed Original ResearchPosttraumatic stress disorderClinical evidenceStress disorderMethyl-d-aspartate (NMDA) receptor antagonistLow patient engagementRobust antidepressant effectsOpen-label studyOnset of actionPotential of ketamineQuality of lifeMedical comorbiditiesAntidepressant effectsChart reviewRefractory casesDisease chronicityClinical presentationRandomized trialsCase reportDevastating conditionReceptor antagonistMajor depressionPharmacological approachesPsychiatric disordersPharmacological agentsTherapeutic safety
2020
Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression?
Abdallah CG, Krystal JH. Ketamine and rapid acting antidepressants: Are we ready to cure, rather than treat depression? Behavioural Brain Research 2020, 390: 112628. PMID: 32407817, PMCID: PMC7316409, DOI: 10.1016/j.bbr.2020.112628.Peer-Reviewed Original ResearchConceptsChronic stress pathologyRapid acting antidepressantsHigh treatment resistanceActing antidepressantsChronic courseClinical evidenceLeading causeTreatment resistancePsychiatric disordersStress pathologyDepressionLarge proportionAntidepressantsPatientsReviewKetamineIllnessPathologyComprehensive review